Phase 1b/2 Study of MEK162 Plus Imatinib in Gastrointestinal Stromal Tumors

Share this content:
For this phase 1b/2 interventional study, researchers are investigating the safety and efficacy of MEK162 plus imatinib among patients with gastrointestinal stromal tumors.
For this phase 1b/2 interventional study, researchers are investigating the safety and efficacy of MEK162 plus imatinib among patients with gastrointestinal stromal tumors.

Title: A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)1

Principal Investigator: Ping Chi, MD, PhD, Memorial Sloan Kettering Cancer Center

Description: For this phase 1b/2 interventional study, researchers are investigating the safety and efficacy of MEK162 plus imatinib among patients with gastrointestinal stromal tumors (GIST).

For the phase 1b portion of the study, eligible patients must have locally advanced or metastatic GIST and must have progressed on imatinib.

Patients in the phase 1b portion of the study will receive imatinib 400 mg once daily plus MEK162 at standard 3+3 escalation doses, and in the phase 1b expansion will receive MEK162 30 mg twice daily and imatinib 400 mg once daily.

For the phase 2 portion of the study, eligible patients must have newly diagnosed GIST, be treatment-naive, or have received the last dose of adjuvant imatinib therapy at least 3 months prior to enrolment.

Phase 2 patients will receive imatinib 400 mg once daily plus MEK162 30 mg twice daily.

The primary outcome for the phase 1b portion of the study is maximum tolerated dose and for the phase 2 portion is best response rate assessed within 32 weeks of treatment. Secondary measures are response rate and progression-free survival.

The estimated enrollment is 62.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01991379.

Status: This study is open and recruiting patients as of September 26, 2017.

This study is sponsored by Memorial Sloan Kettering Cancer Center in collaboration with Array BioPharma and the University of Pittsburgh.

Reference

  1. Clinicaltrials.gov. MEK162 in combination with imatinib mesylate in patients with untreated advanced gastrointestinal stromal tumor (GIST). NCT01991379. https://clinicaltrials.gov/ct2/show/NCT01991379. Accessed September 26, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters